CD47 and neoplasm: Magrolimab is an anti-CD47 antibody that promotes phagocytosis of lymphoma cells in preclinical models, polarizes macrophages from a tumor-tolerant M2 phenotype to an anti-tumor M1 phenotype, and has demonstrated synergy with rituximab in B-cell non-Hodgkin lymphomas [129,130].